In this study it was shown by significantly impairing the effectiveness of treatment with EGFR TKIs, canagliflozin inhibits L858R/T790M EGFR kinase anticancer activity in lung cancer cells that are resistant to EGFR TKIs [158] (Figure 3). This evidence concerns the gene EGFR and lung carcinoma.